Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy

References

• Goebeler M-E, Bargou RC. T cell-engaging therapies — BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418–12. doi:10.1038/s41571-020-0347-5.
   PubMed Web of Science ®Google Scholar
• Wu Z, Cheung NV. T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics. Pharmacol Ther. 2018;182:161–75. doi:10.1016/j.pharmthera.2017.08.005.
   PubMed Web of Science ®Google Scholar
• Vafa O, Trinklein ND. Perspective: designing T-Cell engagers with better therapeutic windows. Front Oncol. 2020;10:446. doi:10.3389/fonc.2020.00446.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68. doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Full FDA Approval for Blinatumomab for ALL - NCI [Internet]. [cited 2023 Oct 2]. https://www.cancer.gov/news-events/cancer-currents-blog/2017/blinatumomab-all-fda-full-approval.
   Google Scholar
• Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, et al. Glofitamab for relapsed or refractory diffuse large B-Cell Lymphoma. N Engl J Med. 2022;387(24):2220–31. doi:10.1056/NEJMoa2206913.
   PubMed Web of Science ®Google Scholar
• Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, et al. Overall survival benefit with tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021;385(13):1196–206. doi:10.1056/NEJMoa2103485.
   PubMed Web of Science ®Google Scholar
• Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505. doi:10.1056/NEJMoa2203478.
   PubMed Web of Science ®Google Scholar
• Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2019;154:102–17. doi:10.1016/j.ymeth.2018.10.026.
   PubMed Web of Science ®Google Scholar
• Leclercq G, Steinhoff N, Haegel H, De Marco D, Bacac M, Klein C. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology. 2022;11(1):2083479. doi:10.1080/2162402X.2022.2083479.
   PubMed Web of Science ®Google Scholar
• Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The Oncologist. 2018;23(8):943–47. doi:10.1634/theoncologist.2018-0028.
   PubMed Web of Science ®Google Scholar
• Cattaruzza F, Nazeer A, To M, Hammond M, Koski C, Liu LY, Pete Yeung V, Rennerfeldt DA, Henkensiefken A, Fox M, et al. Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. Nat Cancer. 2023;4(4):485–501. doi:10.1038/s43018-023-00536-9.
   PubMedGoogle Scholar
• Skrombolas D, Sullivan M, Frelinger JG. Development of an Interleukin-12 fusion protein that is activated by cleavage with matrix metalloproteinase 9. J Interferon Cytokine Res. 2019;39(4):233–45. doi:10.1089/jir.2018.0129.
   PubMed Web of Science ®Google Scholar
• Boustany LM, Wong L, White CW, Diep L, Huang Y, Liu S, Richardson JH, Kavanaugh WM, Irving BA. Abstract A164: EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose> 60-fold in preclinical studies. Mol Cancer Ther. 2018;17(1_Supplement):A164–A164.
   Web of Science ®Google Scholar
• Panchal A, Seto P, Wall R, Hillier BJ, Zhu Y, Krakow J, Datt A, Pongo E, Bagheri A, Chen T-H, et al. COBRA™: a highly potent conditionally active T cell engager engineered for the treaTMent of solid tumors. In MAbs. 2020;12(1):1792130. doi:10.1080/19420862.2020.1792130.
   PubMed Web of Science ®Google Scholar
• Autio KA, Boni V, Humphrey RW, Naing A. Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology. Clin Cancer Res. 2020;26(5):984–89. doi:10.1158/1078-0432.CCR-19-1457.
   PubMed Web of Science ®Google Scholar
• Pejchal R, Cooper AB, Brown ME, Vásquez M, Krauland EM. Profiling the biophysical developability properties of common igg1 fc effector silencing variants. Antibodies (Basel). 2023;12(3):12. doi:10.3390/antib12030054.
   PubMedGoogle Scholar
• https://patentimages.storage.googleapis.com/8e/09/8c/72cfaa03fdd3c6/WO2018213113A1.pdf.
   Google Scholar
• Bortoletto N, Scotet E, Myamoto Y, D’Oro U, Lanzavecchia A. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. Eur J Immunol. 2002;32(11):3102–07. doi:10.1002/1521-4141(200211)32:11<3102:AID-IMMU3102>3.0.CO;2-C.
   PubMed Web of Science ®Google Scholar
• Dushek O, Aleksic M, Wheeler RJ, Zhang H, Cordoba S-P, Peng Y-C, Chen J-L, Cerundolo V, Dong T, Coombs D, et al. Antigen potency and maximal efficacy reveal a mechanism of efficient T cell activation. Sci Signal. 2011;4(176):ra39. doi:10.1126/scisignal.2001430.
   PubMed Web of Science ®Google Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol. 2014;32(2):191–98. doi:10.1038/nbt.2797.
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748. doi:10.1155/2014/852748.
   PubMedGoogle Scholar
• Galogre M, Rodin D, Pyatnitskiy M, Mackelprang M, Koman I. A review of HER2 overexpression and somatic mutations in cancers. Crit Rev Oncol Hematol. 2023;186:103997. doi:10.1016/j.critrevonc.2023.103997.
   PubMed Web of Science ®Google Scholar
• Copeland-Halperin RS, Liu JE, Yu AF. Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol. 2019;34(4):451–58. doi:10.1097/HCO.0000000000000637.
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Shien K, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Asano H, Soh J, Tsukuda K, et al. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. Cancer Sci. 2018;109(4):1166–76. doi:10.1111/cas.13546.
   PubMed Web of Science ®Google Scholar
• Liu CY, Ahonen CL, Brown ME, Zhou L, Welin M, Krauland EM, Pejchal R, Widboom PF, Battles MB. Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity. MAbs. 2023;15(1):2189974. doi:10.1080/19420862.2023.2189974.
   PubMed Web of Science ®Google Scholar
• Geiger M, Stubenrauch K-G, Sam J, Richter WF, Jordan G, Eckmann J, Hage C, Nicolini V, Freimoser-Grundschober A, Ritter M, et al. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. Nat Commun. 2020;11(1):3196. doi:10.1038/s41467-020-16838-w.
   PubMed Web of Science ®Google Scholar
• Rocha SS, Lin R, Dayao MR, Banzon RR, Thothathri S, Wright KJ, Aaron W, Xiao Y, Bergo N, To L, et al. Abstract 2928: TROP2 ProTriTAC™, a protease-activated T cell engager prodrug targeting TROP2 for the treaTMent of solid tumors. Cancer Res. 2023;83(7_Supplement):2928–2928. doi:10.1158/1538-7445.AM2023-2928.
   Web of Science ®Google Scholar
• https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-02213&r=1. [cited 2023 Dec 18].
   Google Scholar
• Chen TT. Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development. Expert Opin Biol Ther. 2022;22(8):955–63. doi:10.1080/14712598.2022.2098674.
   PubMed Web of Science ®Google Scholar
• Liu Y, Nguyen AW, Maynard JA. Engineering antibodies for conditional activity in the solid tumor microenvironment. Curr Opin Biotechnol. 2022;78:102809. doi:10.1016/j.copbio.2022.102809.
   PubMed Web of Science ®Google Scholar
• US Patent Application for BISPECIFIC. ANTI-CD3 ANTIBODIES, BISPECIFIC ACTIVATABLE ANTI-CD3 ANTIBODIES, and METHODS of USING the SAME Patent Application (Application #20210047406 issued February 18, 2021) - Justia Patents Search [Internet]. [cited 2024 May 27]. https://patents.justia.com/patent/20210047406.
   Google Scholar
• Mocquot P, Mossazadeh Y, Lapierre L, Pineau F, Despas F. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. J Clin Pharm Ther. 2022;47(9):1337–51. doi:10.1111/jcpt.13741.
   PubMed Web of Science ®Google Scholar
• Zorn JA, Wheeler ML, Barnes RM, Kaberna J, Morishige W, Harris M, Huang RYC, Lohre J, Chang YC, Chau B, et al. Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model. Sci Rep. 2022;12(1):3530. doi:10.1038/s41598-022-06953-7.
   PubMed Web of Science ®Google Scholar
• Dong D, Zheng L, Lin J, Zhang B, Zhu Y, Li N, Xie S, Wang Y, Gao N, Huang Z. Structural basis of assembly of the human T cell receptor–CD3 complex. Nature. 2019;573(7775):546–52. doi:10.1038/s41586-019-1537-0.
   PubMed Web of Science ®Google Scholar
• Menon AP, Moreno B, Meraviglia-Crivelli D, Nonatelli F, Villanueva H, Barainka M, Zheleva A, van Santen HM, Pastor F. Modulating T cell responses by targeting CD3. Cancers (Basel). 2023;15(4):15. doi:10.3390/cancers15041189.
   Web of Science ®Google Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40(4):658–74. doi:10.1107/S0021889807021206.
   PubMed Web of Science ®Google Scholar
• Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994;50(5):760–63. doi:10.1107/S0907444994003112.
   PubMedGoogle Scholar
• BUSTER version 2.10.0 – ScienceOpen [Internet]. [cited 2024 Feb 2]. https://www.scienceopen.com/document?vid=34a668bc-6e6f-4572-a548-6d19e78e1e30.
   Google Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66(4):486–501. doi:10.1107/S0907444910007493.
   PubMedGoogle Scholar
• Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, et al. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. Mabs-austin. 2015;7(3):470–82. doi:10.1080/19420862.2015.1022694.
   PubMed Web of Science ®Google Scholar
• Froning KJ, Leaver-Fay A, Wu X, Phan S, Gao L, Huang F, Pustilnik A, Bacica M, Houlihan K, Chai Q, et al. Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies. Protein Sci. 2017;26(10):2021–38. doi:10.1002/pro.3240.
   PubMed Web of Science ®Google Scholar
• Leaver-Fay A, Froning KJ, Atwell S, Aldaz H, Pustilnik A, Lu F, Huang F, Yuan R, Hassanali S, Chamberlain AK, et al. Computationally designed bispecific antibodies using negative state repertoires. Structure. 2016;24(4):641–51. doi:10.1016/j.str.2016.02.013.
   PubMed Web of Science ®Google Scholar